La Crosse Method
Why the La Crosse Method doses the way it does
Clinicians sometimes ask why the La Crosse Method uses lower allergen concentrations taken more often, when licensed SLIT tablets use one high dose a day. The answer is that the protocol was built for a different job: treating several environmental and food allergens at once, in patients of every sensitivity level, at a dose each patient tolerates. Its dosing follows from that design.
Key points
- Each starting dose is set from the patient’s testing, history and exam — below the level that provokes symptoms.
- Three doses a day keep allergen in steady contact with the tolerance-building cells under the tongue.
- Strength rises step by step as retesting and tolerance allow, rather than on a fixed schedule.
- One 90-day prescription can cover multiple environmental and food allergens.
- High-dose tablets and the La Crosse approach are both legitimate; they are designed for different patients.
Where the question comes from
Licensed SLIT tablets were developed in large trials as a single high dose taken once a day. The pivotal grass-tablet trial compared three strengths and found the highest one worked best — a clear dose-response for that single-allergen product. It is reasonable to ask how a protocol using lower concentrations compares.
The useful question is not “high or low” in the abstract, but which dose, frequency and duration suit a particular patient and allergen mix. The La Crosse Method answers that question patient by patient.
Why three doses a day
Allergen placed under the tongue is not absorbed straight into the bloodstream. It is held in the mucosa, where dendritic cells capture it and carry it to lymph nodes to train regulatory T cells — the cells behind lasting tolerance. The same tissue has very few of the mast cells that drive allergic reactions, which is a large part of why SLIT is well tolerated.
Dosing three times a day keeps that contact steady throughout the day. An Italian open study of low-dose drops tested exactly this: in the first year, only the three-times-daily group showed reduced skin reactivity, and medication use fell in the twice- and three-times-daily groups but not yet in the once-daily group. The authors concluded that the number of daily administrations appears to correlate with efficacy. Allergy Associates of La Crosse physicians laid out the same mechanistic rationale for dosing, stability and delivery in their 2009 review.
- Frati F et al. Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc 2007
- Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2006
- Theodoropoulos DS, Morris MS, Morris DL. Emerging concepts of sublingual immunotherapy for allergy. Drugs Today 2009
- Allergychoices — Supporting Evidence
Why the dose is individual, not maximal
There is no single proven SLIT dose for every allergen and every patient; reviews of the dosing literature describe the effective range as still to be defined, with frequency and duration mattering alongside dose. The La Crosse Method therefore starts each patient at a strength matched to their test results and raises it as retesting and tolerance allow.
That approach is what lets the protocol treat people who are often hard to treat: patients with many sensitivities, patients with food allergy, and patients with asthma. It also keeps treatment simple — one bottle per treatment set, the same three-times-daily instructions throughout, and a 90-day supply that is adjusted in strength at each refill.
What the protocol’s own studies show
Allergy Associates of La Crosse has published outcomes from patients treated on the protocol. In a prospective study of 51 patients with allergic rhinoconjunctivitis, quality-of-life scores improved significantly on six of seven domains within 10–12 months. In a nine-year review of shrimp-allergic patients, doses began at 64–320 ng and were built up to 0.5 mg three times a day; of 18 patients who took an oral challenge, 61% tolerated 42 g of shrimp or more, with no systemic reactions.
La Crosse Method Protocol outcomes were reviewed by the Validation Institute, an independent team of population health scientists and bio-statisticians, which validated them in 2018 and 2020; that validation expired in July 2022. The population-health results reviewed for those validations are published on the Allergy Control Program results page.
- Morris MS et al. Quality of life improvement with sublingual immunotherapy: a prospective study of efficacy. J Allergy (Cairo) 2012
- Theodoropoulou LM, Cullen NA. Sublingual immunotherapy for allergy to shrimp: the nine-year clinical experience of a Midwest Allergy-Immunology practice. Allergy Asthma Clin Immunol 2024
- Allergychoices — Allergy Control Program validated results
Two legitimate approaches, different patients
High-dose, single-allergen tablets carry the largest regulatory trials and are FDA-approved for specific grass, ragweed and dust mite allergies. The La Crosse Method is built for patient-specific treatment of several allergens at once — environmental and food — at a dose the patient tolerates. Both are effective and generally safe; they fit different patients, and the prescribing provider chooses with the patient.
For the full body of research behind the protocol, see the Allergychoices SLIT bibliography, the supporting-evidence summaries and the list of La Crosse Method author publications.
Frequently asked questions
Is low-dose sublingual immunotherapy effective?
Low-dose SLIT given frequently has published support. In an open study of grass- and birch-allergic patients using one-fifth of the manufacturer’s maintenance concentration, patients dosing three times daily reduced skin reactivity and medication use, and La Crosse practice studies report quality-of-life gains and food tolerance on the protocol. Single high-dose tablets have the largest trials; the two approaches are designed for different patients.
- Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2006
- Morris MS et al. Quality of life improvement with sublingual immunotherapy: a prospective study of efficacy. J Allergy (Cairo) 2012
- Theodoropoulou LM, Cullen NA. Sublingual immunotherapy for allergy to shrimp: the nine-year clinical experience of a Midwest Allergy-Immunology practice. Allergy Asthma Clin Immunol 2024
- Durham SR et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial. J Allergy Clin Immunol 2006
Why does the La Crosse Method use three doses a day?
Frequent dosing keeps allergen in steady contact with the dendritic cells under the tongue that train the immune system toward tolerance. A study comparing one, two and three daily doses found the three-times-daily group improved soonest.
Why not simply use the highest dose a patient can tolerate?
Because the effective SLIT dose range is not fixed, and many La Crosse patients are treated for several allergens or for food allergy at once. Starting at a test-matched strength and raising it with retesting keeps treatment comfortable while tolerance builds.
Has the La Crosse Method been independently validated?
La Crosse Method Protocol outcomes were reviewed by the Validation Institute, an independent team of population health scientists and bio-statisticians, which validated them in 2018 and 2020; that validation expired in July 2022.
Regulatory status
A small number of sublingual immunotherapy (SLIT) tablets are FDA-approved for specific allergens. Personalized allergy drops are compounded by a pharmacy for each patient and prescribed off-label — a long-standing, legitimate practice with decades of use, and SLIT is a first-line prescription approach in much of Europe. Compounded allergy drops are not FDA-approved, but they are created using FDA-approved allergenic extracts, the same as in allergy shots. Off-label does not mean unsafe or experimental.
Related reading
Sources
- Durham SR et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial. J Allergy Clin Immunol 2006 (PMID 16630937) — 855 adults; three tablet strengths vs placebo; dose-dependent efficacy.
- Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2006 (PMID 16937744) — Open study; 64 patients; once, twice and three-times-daily schedules.
- Frati F et al. Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc 2007 (PMID 17390755)
- Theodoropoulos DS, Morris MS, Morris DL. Emerging concepts of sublingual immunotherapy for allergy. Drugs Today 2009 (PMID 20069138) — Allergy Associates of La Crosse.
- Larenas-Linnemann DE. Sublingual immunotherapy: dosing in relation to clinical and immunological efficacy. Allergy Asthma Proc 2008 (PMID 18430309)
- Morris MS et al. Quality of life improvement with sublingual immunotherapy: a prospective study of efficacy. J Allergy (Cairo) 2012 (PMID 22500181) — Allergy Associates of La Crosse; 51 patients.
- Theodoropoulou LM, Cullen NA. Sublingual immunotherapy for allergy to shrimp: the nine-year clinical experience of a Midwest Allergy-Immunology practice. Allergy Asthma Clin Immunol 2024 (PMID 38734651) — Allergy Associates of La Crosse; 66 patients.
- FDA — Allergen Extract Sublingual Tablets
- Allergychoices — About the La Crosse Method Protocol
- Allergychoices — The La Crosse Method Difference
- Allergychoices — Supporting Evidence
- Allergychoices — Sublingual Immunotherapy Research Bibliography
- Allergychoices — La Crosse Method Protocol Author Research
- Allergychoices — Allergy Control Program validated results
